Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.54 |
| ▸ | LIPE | Q05469 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 8/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677114 | 0.89 | EPHX1 (0.62) | EPHX2LMNAHTTSMN1; SMN2EPHX1 | |
| SCHEMBL1676975 | 0.85 | EPHX2 (0.56) | EPHX2LMNAHTTSMN1; SMN2EPHX1 | |
| SCHEMBL1677039 | 0.84 | EPHX2 (0.56) | EPHX2SMN1; SMN2EPHX1LIPECYP1A2 | |
| SCHEMBL1677174 | 0.84 | EPHX2 (0.63) | EPHX2SMN1; SMN2EPHX1LIPENAMPT | |
| SCHEMBL1677076 | 0.84 | EPHX2 (0.66) | RAB9AEPHX2SMN1; SMN2EPHX1LIPE | |
| SCHEMBL1676986 | 0.84 | EPHX2 (0.55) | EPHX2LMNAHTTEPHX1LIPE | |
| SCHEMBL1677065 | 0.84 | EPHX2 (0.56) | NPC1RAB9AEPHX2LMNAHTT | |
| SCHEMBL1677281 | 0.83 | EPHX2 (0.62) | EPHX2SMN1; SMN2EPHX1LIPECYP1A2 | |
| SCHEMBL1677160 | 0.83 | EPHX2 (0.54) | NPC1RAB9AEPHX2LMNAEPHX1 | |
| SCHEMBL1677026 | 0.82 | EPHX2 (0.53) | EPHX2LMNAHTTEPHX1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-2346820-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| WO-2009151152-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | NPC1 963/4885RAB9A 2277/4885EPHX2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.